Limitations of transoesophageal echocardiogram in acute ischaemic stroke

Zachary P Rosol,1 Kathleen F Kopecky,1 Bailey R Minehart,1 Kristen M Tecson 2 Anupama Vasudevan,2 Peter A McCullough,1,3 Paul A Grayburn1,3

Jeffrey M Schussler1,3

ABSTRACT

Objective The role of transoesophageal echocardiography (TOE) in identifying ischaemic stroke aetiology is debated. In 2018, the American Heart Association/American Stroke Association (AHA/ASA) issued class IIa recommendation for echocardiography, with the qualifying statement of use in cases where it will alter management. Hence, we sought to determine the rate at which TOE findings altered management in cases of confirmed ischaemic stroke.

Methods We retrospectively analysed TOE cases with confirmed ischaemic stroke at our centre between April 2015 and February 2017. We defined a change in management as the initiation of anticoagulation therapy, antibiotic therapy or patent foramen ovale closure as a direct result of TOE findings.

Results There were 185 patients included in this analysis; 19 (10%) experienced a change in management. However, only 7 of the 19 (4% of all subjects) experienced a change in management due to TOE findings. The remaining 12 were initiated on oral anticoagulation as a result of discoveries during routine workup, mainly atrial fibrillation on telemetry monitoring.

Conclusions This work suggests an overuse of TOE and provides support for the 2018 AHA/ASA stroke guidelines, which recommend against the routine use of echocardiography in the workup of cerebrovascular accident due to a cardioembolic source.

INTRODUCTION

Ischaemic and haemorrhagic stroke remain the fifth leading cause of death in the USA, accounting for 1 in every 19 deaths.1 Every year in the USA, over 795 000 patients experience their first stroke, with an additional 180 000 having a recurrent event.1 Costs associated with treating strokes account for approximately 1.5% of total healthcare spending.2 Of all strokes, 87% are ischaemic, and 13%–40% of those are due to a cardioembolic source.2 To determine a stroke’s aetiology, transoesophageal echocardiography (TOE) may be used if a cardioembolic or cryptogenic source is suspected. However, the benefit of TOE over other procedures (eg, MRI and transthoracic echocardiogram (TTE)), is debated and may come with additional risks including exposure to anaesthesia, prolonged hospital stay and incurred expense. In 2018, the American Heart Association/American Stroke Association (AHA/ASA) issued a class IIa recommendation for the use of echocardiography for cases in which it will alter management.3 As it is our hypothesis that TOE is overused in patients with ischaemic stroke, we sought to identify the rate at which management changes due to TOE in patients hospitalised with acute ischaemic stroke (AIS).
Methods
We performed a retrospective analysis using the Baylor University Medical Center’s Lumendx Apollo database to identify patients with AIS who underwent a TOE for the indication of cerebrovascular accident (CVA) between April 2015 and February 2017. This was accomplished by first limiting cases to TOEs, confirming AIS via imaging and filtering based on indication. We reviewed qualifying patient charts and categorised strokes based on the Trial of Org 10172 in Acute Stroke Treatment (TOAST) classification. In short, the TOAST classification system uses clinical features, imaging and laboratory assessments to diagnose five subtypes of ischaemic stroke (large artery atherosclerosis, cardioembolism, small-vessel occlusion, stroke of other determined aetiology and stroke of undefined aetiology) with probable or possible certainty. We additionally abstracted information on patient comorbidities and medications from electronic medical records. We defined a change in management as the initiation of anticoagulation therapy, antibiotic therapy or patent foramen ovale (PFO) closure as a direct result of TOE findings. We calculated the rate of management change for all patients with confirmed AIS who underwent a TOE for CVA. This study was approved by the Baylor Scott & White Research Institute’s Institutional Review Board with a waiver of informed consent. Categorical variables are presented as frequency (percentage) and continuous variables as mean±SD or median (quartile 1, quartile 3), as appropriate. Data management and analyses were performed using SAS V.9.4.

PATIENT AND PUBLIC INVOLVEMENT
Neither patients nor the public were involved in the design, or conduct, or reporting, or dissemination of this research.

RESULTS
There were 280 patients who underwent a TOE for the indication of ischaemic stroke during the study period; 185 (66%) met this study’s criteria of having a confirmed AIS by imaging and indication of CVA (table 1). Nineteen (10%) patients were initiated on OAC at discharge; however, only 7 of the 19 (37%; 4% of all subjects) actually experienced a change in medical management due to TOE findings (table 2). The remaining 12 were initiated on OAC as a result of discoveries during routine workup, mainly atrial fibrillation on telemetry monitoring. There were two (1%) thrombus cases identified via TOE (figure 1). Interestingly, there were 22 (12%) PFO cases, five (23%) of which were initiated on OAC prior to discharge; however, none were started on OAC for the indication of PFO alone. Closure recommendations are provided by neurologists at our centre; however, no patients with a PFO underwent device closure prior to discharge in this study.

DISCUSSION
In this study of 185 subjects hospitalised with confirmed AIS who underwent a TOE, only 7 (4%) experienced a change in management, as defined as the initiation of anticoagulation therapy, antibiotic therapy or PFO closure as a direct result of TOE findings. The majority (63%) of patients initiated on OAC were started based on the findings from routine, less invasive and more cost-effective testing such as telemetry, TTE and carotid ultrasound.

As it relates to CVA, TOE is more sensitive to assess for valvular vegetations, left atrial appendage thrombus and
PFO than is TTE. Multiple studies have investigated the role of TOE in the workup for stroke and have mixed conclusions and recommendations. In spite of these studies, previous guidelines remained vague with respect to the proper use of TOE, and there are limited observational data showing how TOE findings impact management. Furthermore, the rates of TOE findings causing a change in management vary across studies. For example, Pallesen and colleagues and Katsanos and colleagues showed 9% of cases resulted in management change, while Marino and colleagues revealed that, despite having high diagnostic value, TOE findings changed medical management in only 0.4% of cases in their study. Hence, our result of 4% is intermediary. The AHA/ASA 2018 updated guidelines for AIS deviate from prior iterations by directly addressing cardiac workup in stroke, acknowledging the role of prolonged cardiac monitoring, with a ‘f’ recommendation in ‘select patients’. In addition, and in line with our findings, the routine use of echocardiography in all patients with acute ischaemic stroke to plan subsequent secondary preventive treatment is not cost-effective and is not recommended. The American Society for Echocardiography (ASE) published guidelines in 2011 for the use of echocardiography in the evaluation of cardiac source of embolism. The indications include having a non-diagnostic TTE, evaluating for cardiovascular source of embolus without other non-cardiac source, to assess valvular structure and to diagnose infective endocarditis. Significant valvular structural problems that pose a risk for thromboembolic phenomenon should be detectable by TTE. In addition, the diagnosis of infective endocarditis (a separate indication for TOE) should be accompanied by consistent clinical findings. The ASE guidelines state that the use of TOE is ‘inappropriate and not reasonable’ when TOE results would not change management.

Newer studies have demonstrated increased detection of atrial fibrillation in patients with prolonged monitoring after AIS. While often clinically suspected, the role of and proper treatment for silent atrial fibrillation has been difficult for physicians to decipher. The absence of left atrial thrombus on TOE does not confer the absence prior to AIS. Initiation of OAC therapy without evidence of thrombogenic rhythm is not recommended at this time; hence, increased bleeding risk has justifiably prevented most physicians from initiating OAC. Instead, the focus has been on antiplatelet therapy, which has demonstrated a marginal benefit in reducing subsequent stroke.

This single centre study has notable limitations. In our institution, a TOE is often ordered on admission by a hospitalist (per protocol) or by neurologists as a component of initial stroke workup. It is even occasionally performed prior to a TTE or confirming stroke by imaging due to heavy MRI use among hospitalised patients and its time-consuming nature compared with CT imaging. However, we acknowledge that not all centres operate in the same manner. We could not adequately compare the value of TTE versus TOE, as many patients underwent TOE alone. Additionally, our definition of change in management was limited to the time period of the initial hospitalisation; if a patient was started on OAC, had extended cardiac rhythm monitoring as an outpatient or underwent percutaneous PFO device closure after discharge, those results were not captured in this analysis. Finally, although recent clinical trials indicate that PFO closure in addition to long-term antithrombotic treatment likely reduces the recurrence of stroke in patients aged 60 years or younger such that the benefits outweigh the risks, our study was conducted during a time of more uncertainty about PFO closure outcomes.

CONCLUSION
A change in medical management due to TOE findings occurred in only 4% of patients who underwent a TOE for AIS in this study. This low rate provides support for the 2018 AHA/ASA stroke guidelines, which recommend against the routine use of TOE in the workup of AIS. Given that AIS aetiology is often discovered via less invasive technologies, the use of TOE must be used in the appropriate clinical setting, likely after a thorough neurological workup has been performed. Further consideration is needed for prolonged rhythm monitoring for atrial arrhythmias and the initiation of novel oral anticoagulation. Limiting the use of TOE may reduce cost and exposure to unnecessary testing, as well as potentially facilitate earlier discharge for patients.

Contributors ZPR contributed to the design, interpretation and draft. KFK, BRM, KMT and AV contributed to data acquisition and critical revision. PAM, PAG and JMS contributed to interpretation and critical revision. All authors approve and agree to be accountable of this work.

Funding This work was partially funded by the Baylor Health Care System Foundation.

Competing interests None declared.

Patient consent for publication Not required.
REFERENCES

1. Mozaffarian D, Benjamin EJ, AS G, et al. Heart disease and stroke Statistics-2016 update: a report from the American heart association, Circulation 2016;133:e38–60.

2. Kolominsky-Rabas PL, Weber M, Gefeller O, et al. Epidemiology of ischemic stroke subtypes according to TOAST criteria. Stroke 2001;32:2735–40.

3. Powers WJ, Rabinstein AA, Ackerson T, et al. 2018 guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American heart Association/ American stroke association. Stroke 2018;49:e46–110.

4. Adams HP, Bendixen BH, Kappelle LJ, et al. Classification of subtype of acute ischemic stroke. definitions for use in a multicenter clinical trial. TOAST, trial of ORG 10172 in acute stroke treatment. Stroke 1993 ;24(4):35–41.

5. Saric M, Armour AC, Arnaout MS, et al. Guidelines for the use of echocardiography in the evaluation of a cardiac source of embolism. J Am Soc Echocardiogr 2016;29:1–42.

6. Ustrell X, Pellise A, Ustrell X, Pellisé A. cardiac workup of ischemic stroke: can we improve our diagnostic yield? Stroke 2009;40:2893–8.

7. Schwartz BG, Chris Alexander MD, MD Paul A, Grayburn, MD, et al. Utility of routine transesophageal echocardiography in patients with stroke or transient ischemic attack utility of routine transesophageal echocardiography in patients with stroke or transient ischemic attack Brian G. Schwartz, MD 2, Chris Alexander. . Baylor Univ Med Cent 2018. 6.

8. Nishimura RA, Otto CM, Bonow RO, et al. 2017 AHA/ACC Focused Update of the 2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol 2017;70:252–89.

9. Pallesen L-P, Ragaller M, Kepplinger J, et al. Diagnostic impact of transesophageal echocardiography in patients with acute cerebral ischemia. Echocardiography 2016;33:555–61.

10. Katsanos AH, Bhole R, Frogoudaki A, et al. The value of transesophageal echocardiography for embolic strokes of undetermined source. Neurology 2016;87:988–95.

11. Marino B, Jaiswal A, Goldbarg S, et al. Impact of transesophageal echocardiography on clinical management of patients over age 50 with cryptogenic stroke and normal transthoracic echocardiogram. J Hosp Med 2016;11:95–8.

12. Wachter R, Gröschel K, Gelbrich G, et al. Holter-electrocardiogram-monitoring in patients with acute ischaemic stroke (Find- AF RANDOMISED): an open-label randomised controlled trial. Lancet Neurol 2017;16:282–90.

13. Sanna T, Diener H-C, Passman RS, et al. Cryptogenic stroke and underlying atrial fibrillation. N Engl J Med 2014;370:2478–86.

14. Gladstone DJ, Spring M, Dorian P, et al. Atrial fibrillation in patients with cryptogenic stroke. N Engl J Med 2014;370:2467–77.

15. Wang Y, Wang Y, Zhao X, et al. Clopidogrel with aspirin in acute minor stroke or transient ischemic attack. N Engl J Med 2013;369:11–19.

16. Diener H-C, Bogousslavsky J, Brass LM, et al. Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (match): a randomised, double-blind, placebo-controlled trial. Lancet 2004;364:331–7.

17. Bhatt DL, Fox KAA, Hacke W, et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med 2006;354:1706–17.

18. Gouya G, Arrich J, Wolzt M, et al. Antiplatelet treatment for prevention of cerebrovascular events in patients with vascular diseases: a systematic review and meta-analysis. Stroke 2014;45:492–503.

19. Köhmann M, Schellinger PD, Tsivgoulis G, et al. Patent foramen ovale: story closed? J Stroke 2019;21:23–30.